Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Pharma

Global rheumatoid arthritis market set to reach $29.1bn by 2029

The rheumatoid arthritis (RA) market is expected to grow from $26.2bn in 2019 to $29.1bn in 2029 across the eight major markets (8MM*) at a compound annual growth rate (CAGR) of 1.0%, according to GlobalData, a leading data and analytics company. The company’s latest report, ‘Rheumatoid Arthritis: Global Drug Forecast and Market Analysis to 2029’, reveals that although the […]
Read more

Focusing on improving patient’s quality of life could advance supportive care in cancer, says GlobalData

Technological advancements in oncology, such as the introduction of immuno-oncology therapies and targeted therapies, have improved quality of life (QoL) compared to conventional treatment options, such as chemotherapy regimens. Although disparities exist between individual indications within supportive care in cancer (SCC), a concerted effort on improving QoL and an increased understanding of disease mechanisms that […]
Read more

Teva Pharmaceuticals and MedinCell’s LAI mdc-IRM faces an increasingly competitive schizophrenia market

Teva Pharmaceuticals and MedinCell are seeking to enter the long-acting injectable (LAI) schizophrenia market after their LAI mdc-IRM (risperidone ER) demonstrated a statistically significant increase in time to relapse, compared to placebo in a Phase III trial (RISE Study). However, mdc-IRM will face an increasingly competitive schizophrenia market with LAIs being developed for many of […]
Read more

Evolving type 2 diabetes digital marketing space in Japan requires existing players attention, says GlobalData

The Japanese type 2 diabetes (T2D) therapeutics market is highly competitive with several generic, branded and biosimilar products available. Among the various types of therapies, the leading class of drugs are GLP-1R agonists, DPP-4 inhibitors and SGLT-2 inhibitors. Considering the intense competition and the growth opportunities, the digital support available for T2D patients through branded […]
Read more

Pfizer-BioNTech COVID-19 vaccine has forecasted whopping $30bn in sales

Pfizer-BioNTech’s two-shot mRNA COVID-19 vaccine, BNT-162b2, is currently the leading prophylactic vaccine for COVID-19 based on forecast sales as it is expected to be the first globally available vaccine for COVID-19. BNT-162b2 is expected to generate a whopping $30bn in sales from 2020 to 2026, with peak sales of $13.9bn in 2021, says GlobalData, a […]
Read more

Pricing and reimbursement concerns remain leading impediment to industry growth in 2021, says GlobalData

In 2021, drug pricing pressure from regulators and payers will remain and aggressive negotiation tactics to drive down drug prices will continue, according to GlobalData, a leading data and analytics company. The company’s latest annual outlook report, ‘The State of the Biopharmaceutical Industry – 2021’, reveals that 49% of global industry survey respondents believe that […]
Read more

Urban China to have highest diagnosed incident cases of non-small cell lung cancer over next decade, forecasts GlobalData

Urban China is expected to have the highest number of diagnosed incident cases of non-small cell lung cancer (NSCLC) among the eight major markets 8MM* over the next decade (2019­-2029), according to GlobalData, a leading data and analytics company. GlobalData’s latest report, ‘Non-Small Cell Lung Cancer – Epidemiology Forecast Report to 2029, reveals that the […]
Read more

Diagnosed incident cases of hepatocellular carcinoma in urban China set to rise by 44.41% over next decade, forecasts GlobalData

The diagnosed incident cases of hepatocellular carcinoma (HCC) in urban China are expected to increase by 44.41% over the next decade (2019­-2029), according to GlobalData, a leading data and analytics company. GlobalData’s latest report, ‘Hepatocellular Carcinoma – Epidemiology Forecast Report to 2029, reveals that the diagnosed incident cases of HCC are expected to increase from […]
Read more

49% of clinical trial disruption due to slow enrollment

As of November 30, 2020, the top reason for disrupted clinical trials is slow enrollment, which is causing delays in 49% of trials. The other main reasons for disruptions are enrollment suspension at 35%, and delayed initiation at 16%, says GlobalData, a leading data and analytics company. Scotty Chung-Siu, Pharma Analyst at GlobalData, comments: “Although suspended […]
Read more

KBP Biosciences’ KBP-5074 has potential to become viable competitor to MRAs for CKD

KBP Biosciences recently shared results for its BLOCK-CKD Phase IIb study and the positive trial results suggest KBP-5074 may become a viable competitor to the already established non-steroidal mineralocorticoid receptor antagonists (MRAs) for chronic kidney disease (CKD), according to GlobalData, a leading data and analytics company. According to GlobalData’s Pharma Intelligence Center (PIC) drug database, KBP Biosciences has two leading products in development: KBP-5074 for uncontrolled hypertension in advanced CKD and KBP-7072 for infectious disease. Kajal Jaddoo, Associate Pharma Analyst at GlobalData, comments: “A benefit of KBP-5074 over other […]
Read more

Entresto’s potential first-mover advantage in largely untapped HFpEF market could be extremely lucrative for Novartis

A positive recommendation from an FDA Advisory Committee has set Novartis’ Entresto (sacubitril/valsartan) on track to become the first drug to be approved for the treatment of heart failure with preserved ejection fraction (HFpEF). The potential label expansion could prove to be extremely lucrative for Novartis, providing the company with a first-mover advantage in this […]
Read more

NovoNordisk’s Rybelsus a game changer in T2D but may face a tough road ahead as it strides into Alzheimer’s space

NovoNordisk’s decision to investigate its recently launched Type 2 Diabetes (T2D) drug Rybelsus (semaglutide) in a pivotal Phase IIIa study of patients with early Alzheimer‘s disease may allow the company to secure its position in yet another lucrative market. However, while this drug will benefit from being the first-to-market oral GLP-1RA in T2D space and capture a […]
Read more

Renal denervation market demonstrates tremendous opportunity following FDA breakthrough device designation

SoniVie and ReCor Medical both recently received US Food and Drug Administration (FDA) breakthrough device designation for their TIVUS and Paradise renal denervation systems. With few manufacturers in the field and a market opportunity of almost 10 million hypertensive patients each year, the breakthrough designation puts ReCor Medical and SoniVie far ahead of larger manufacturers […]
Read more

COVID-19 has left a third of areas in America with limited ICU capacity

The growing rate of new COVID-19 cases indicates the US is facing a major crisis of hospital shortages not yet seen in this pandemic, and there is an expected near-doubling of hospitalizations and intensive care unit (ICU) admissions before year’s end, says GlobalData, a leading data and analytics company. Topias Lemetyinen, Pharma Analyst at GlobalData, […]
Read more

COVID-19 deals boost South Korea’s pharmaceutical industry growth

South Korea’s pharmaceutical sector is becoming increasingly innovative and attractive to foreign investment only 18 months into the government’s $1.7bn five-year biotech plan. The country’s pharmaceutical industry is now poised to grow further due to its preparations to manufacture large amounts of COVID-19 vaccines for domestic and foreign markets, says GlobalData, a leading data and […]
Read more
1 … 73 74 75 76 77 … 110